Search research articles
Contact Us
Filters
Showing results (31-40 of 66) with videos related to
Page
of 7
Sort By:
Pediatric Blood & Cancer
|
February 7, 2022
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials
Josephine H Haduong, Christine M Heske, Wendy Allen-Rhoades, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2004
Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group
Sheri L Spunt, Lynette M Smith, Frederick B Ruymann, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 24, 2018
Treatment Approach and Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group
Julie A Bradley, Mark L Kayton, Yueh-Yun Chi, et al.
Cancer
|
September 20, 2013
Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group
David A Rodeberg, Julie A Stoner, Norbert Garcia-Henriquez, et al.
International Journal of Cancer
|
February 4, 2020
Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group
Timothy B Lautz, Yueh-Yun Chi, Jing Tian, et al.
Cancer
|
May 9, 2019
Risk-based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group
Leo Mascarenhas, Elizabeth R Lyden, Philip P Breitfeld, et al.
International Journal of Cancer
|
June 12, 2020
Impact of local control and surgical lymph node evaluation in localized paratesticular rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
Jonathan C Routh, Roshni Dasgupta, Yueh-Yun Chi, et al.
Journal of Pediatric Surgery
|
September 10, 2021
Pediatric solid tumors and associated cancer predisposition syndromes: Workup, management, and surveillance. A summary from the APSA Cancer Committee
Christa N Grant, Daniel Rhee, Elisabeth T Tracy, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 4, 2025
Radiation Therapy Dose Escalation Failed to Improve Local Control for Intermediate-Risk Rhabdomyosarcoma on ARST1431: A Report From the Children's Oncology Group
Christopher B Jackson, Wei Xue, Abha A Gupta, et al.
Pediatric Blood & Cancer
|
September 1, 2010
Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group
R Beverly Raney, James R Anderson, Kenneth L B Brown, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 66) with videos related to
Sort By:
Page
of 7
Pediatric Blood & Cancer
|
February 7, 2022
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials
Josephine H Haduong, Christine M Heske, Wendy Allen-Rhoades, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2004
Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group
Sheri L Spunt, Lynette M Smith, Frederick B Ruymann, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 24, 2018
Treatment Approach and Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group
Julie A Bradley, Mark L Kayton, Yueh-Yun Chi, et al.
Cancer
|
September 20, 2013
Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group
David A Rodeberg, Julie A Stoner, Norbert Garcia-Henriquez, et al.
International Journal of Cancer
|
February 4, 2020
Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group
Timothy B Lautz, Yueh-Yun Chi, Jing Tian, et al.
Cancer
|
May 9, 2019
Risk-based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group
Leo Mascarenhas, Elizabeth R Lyden, Philip P Breitfeld, et al.
International Journal of Cancer
|
June 12, 2020
Impact of local control and surgical lymph node evaluation in localized paratesticular rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
Jonathan C Routh, Roshni Dasgupta, Yueh-Yun Chi, et al.
Journal of Pediatric Surgery
|
September 10, 2021
Pediatric solid tumors and associated cancer predisposition syndromes: Workup, management, and surveillance. A summary from the APSA Cancer Committee
Christa N Grant, Daniel Rhee, Elisabeth T Tracy, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 4, 2025
Radiation Therapy Dose Escalation Failed to Improve Local Control for Intermediate-Risk Rhabdomyosarcoma on ARST1431: A Report From the Children's Oncology Group
Christopher B Jackson, Wei Xue, Abha A Gupta, et al.
Pediatric Blood & Cancer
|
September 1, 2010
Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group
R Beverly Raney, James R Anderson, Kenneth L B Brown, et al.
Page
of 7